LigoCyte Pharmaceuticals

About:

LigoCyte Pharmaceuticals is focused on developing vaccines and monoclonal antibodies for gastrointestinal and respiratory indications.

Website: http://www.ligocyte.com

Top Investors: Eight Roads Ventures, JAFCO, Novartis Venture Fund, Forward Ventures, Athenian Venture Partners

Description:

LigoCyte is breaking new ground in the treatment of inflammatory and infectious disease. We have produced a number of novel drug compounds to modify immune responses by focusing on cell binding interactions and their role in the immune system. Immunomodulatory drugs represent one of the most exciting areas of pharmaceutical research today, addressing the disease process itself rather than simply treating the resulting symptoms. LigoCyte is advancing its proprietary products into human clinical testing, positioning the company for continued growth and success in the biotechnology industry.

Total Funding Amount:

$43.6M

Headquarters Location:

Bozeman, Montana, United States

Founded Date:

1998-01-01

Founders:

Number of Employees:

11-50

Last Funding Date:

2012-06-28

IPO Status:

Private

Industries:

© 2025 bioDAO.ai